[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607253":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":16,"locations":7,"responsibleParty":22,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":7,"studyType":38,"phases":7,"briefSummary":39,"conditions":40,"keywords":42,"overallStatus":44,"whyStopped":7,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor","evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors",[14,15],"Empagliflozin","Dapagliflozin",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Abanoub Fayoumy Shawky, Bachelor","CONTACT","+201207937601","abanoubfayoumy97@gmail.com",{"type":23,"investigatorFullName":24,"investigatorTitle":25,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Abanoub Fayoumy Shawky","Doctor","100607253","effect-of-sodium-glucose-co-transporter-2-inhibitors-on-left-atrial-remodeling-in-diabetic-patients-100607253",false,"NCT07186153","Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients","Inclusion Criteria:\n\n* Diagnosed T2DM on antidiabetic medication not including SGLT2 inhibitors.\n* HbA1c ≤ 7%.\n* Age 40-75 years.\n* Sinus rhythm.\n* Informed consent obtained\n\nExclusion Criteria:\n\n* History of atrial fibrillation or flutter.\n* Patients treated with SGLT2 inhibitors.\n* Severe mitral valve regurgitation or stenosis.\n* Previous myocardial infarction.\n* Previous percutaneous coronary intervention(PCI) or coronary artery bypass grafting (CABG).\n* LV Ejection fraction \\\u003C50% .\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (BP \\> 160\u002F100 mmHg)\n* Inadequate echocardiographic windows or incomplete data","ALL","40 Years","75 Years",{"count":36,"type":37},100,"ESTIMATED","OBSERVATIONAL","To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after treatment with SGLT2 inhibitors",[41],"SGLT 2 Inhibitors",[43],"left atrial remodelling","NOT_YET_RECRUITING","2025-09-15",{"date":47,"type":48},"2025-09-22","ACTUAL",{"date":50,"type":37},"2025-10-01",{"date":52,"type":37},"2026-11-01",{"name":5,"class":6}]